Why Wall Street Is Becoming Even More Bullish About This Dividend King

Abbott reported Q2 2026 sales growth of 13% to approximately $12.6 billion and adjusted EPS of $1.31, prompting it to raise full-year adjusted EPS guidance to $5.45-$5.60. Medical Devices generated nearly $6 billion in quarterly sales and grew 8.4% organically, supported by diabetes and electrophysiology, while the $21 billion Exact Sciences acquisition expands Abbott's cancer-screening platform. Analysts lifted price targets as high as $143, although Abbott's roughly 33x earnings valuation, weaker Nutrition and Diagnostics sales, and near-term acquisition dilution leave limited room for execution setbacks.

Analysis

ABT now requires Medical Devices to offset a structurally weaker mix elsewhere, making segment-level execution—not the dividend record—the valuation driver. At a low-30s earnings multiple, the stock has limited tolerance for decelerating Libre adoption, electrophysiology procedure-volume normalization, or integration-related dilution; a 1-2 point miss to organic-growth expectations could plausibly drive 10-15% multiple compression. The more consequential question is whether the acquired cancer-screening franchise can lower customer-acquisition costs and expand payer coverage, rather than merely add revenue at a lower margin.

Near term, consensus upgrades create a favorable momentum setup into the next earnings print, but crowded bullish positioning raises the bar for upside. Over 6-18 months, ABT's acquisition financing, restructuring charges, and working-capital needs could constrain incremental capital returns even if adjusted EPS rises. Competitively, DXCM is the cleanest read-through risk: more aggressive Libre pricing or channel incentives to protect share would pressure both companies' CGM gross margins; BSX and MDT offer alternative exposure to procedure growth without ABT's diagnostics and integration overhang.

The contrarian view is that the market may be over-crediting synergy timing while underweighting reimbursement and retention risk in screening diagnostics. A durable upside case requires evidence that acquired testing volumes are growing independently of promotional spend and that free-cash-flow conversion improves—not just adjusted earnings accretion. Falsifiers are a cut to organic-sales guidance, Medical Devices growth below high-single digits, adverse CGM share data, or a material increase in integration costs at the next two reporting dates.

Key Decisions for Investors

• Do not chase ABT immediately after analyst-target momentum. Establish a starter long only on a post-earnings pullback or after confirmation that Medical Devices growth remains at least high-single-digit; target 8-12% upside over 6-12 months, with a thesis stop on organic-growth guidance falling below 6%.
• For healthcare growth exposure, use a 3-6 month pair: long ABT / short DXCM in equal beta-adjusted notional only if channel data show Libre share gains without ABT gross-margin erosion. The trade captures potential share transfer, but exit if DXCM demonstrates renewed U.S. CGM growth acceleration or ABT signals price-led Libre growth.
• Prefer BSX over ABT for investors seeking electrophysiology/procedure-volume exposure over 6-18 months: BSX offers a cleaner operating thesis with less cancer-diagnostics integration and balance-sheet execution risk. Reassess if EP growth slows materially or valuation premium expands beyond ABT without corresponding earnings revisions.
• Set an alert for the next cash-flow disclosure: if acquisition-related outflows and restructuring prevent free-cash-flow conversion from improving despite EPS growth, reduce ABT exposure. That outcome would challenge the basis for dividend-growth and multiple-expansion expectations.